Discounted Cash Flow
Mirum Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | — | $-52.6m | $-39.6m | — | $-4.58 |
| 2020 | $0 | $-103.3m (-96.5%) | $-89.3m (-125.3%) | — | $-4.09 (10.7%) |
| 2021 | $19.1m | $-84.0m (18.7%) | $-132.8m (-48.7%) | -438.9% | $-2.77 (32.3%) |
| 2022 | $77.1m (302.7%) | $-135.7m (-61.5%) | $-120.4m (9.3%) | -176.0% (59.9%) | $-4.01 (-44.8%) |
| 2023 | $186.4m (141.8%) | $-163.4m (-20.5%) | $-71.1m (41.0%) | -87.7% (50.2%) | $-4.00 (0.2%) |
| 2024 | $336.9m (80.8%) | $-87.9m (46.2%) | $9.3m (113.1%) | -26.1% (70.2%) | $-1.85 (53.8%) |
| 2025 | $521.3m (54.7%) | $-23.4m (73.4%) | $54.9m (488.0%) | -4.5% (82.8%) | $-0.47 (74.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.